Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 23345000)

1.

Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors.

Stuurman FE, Voest EE, Awada A, Witteveen PO, Bergeland T, Hals PA, Rasch W, Schellens JH, Hendlisz A.

Invest New Drugs. 2013 Aug;31(4):959-66. doi: 10.1007/s10637-013-9925-z. Epub 2013 Jan 24.

PMID:
23345000
2.

Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.

Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, Kloeker-Rhoades S, Andre VA, Beijnen JH, Slapak CA, Schellens JH.

Clin Cancer Res. 2008 Jun 1;14(11):3477-86. doi: 10.1158/1078-0432.CCR-07-4521.

3.

Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.

Galatin PS, Advani RH, Fisher GA, Francisco B, Julian T, Losa R, Sierra MI, Sikic BI.

Invest New Drugs. 2011 Oct;29(5):971-7. doi: 10.1007/s10637-010-9416-4. Epub 2010 Mar 28.

PMID:
20349264
5.

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.

Deenen MJ, Kl├╝mpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH, Schellens JH, Wilmink JW.

Invest New Drugs. 2012 Aug;30(4):1557-65. doi: 10.1007/s10637-011-9723-4. Epub 2011 Aug 2.

6.

Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.

Guo F, Letrent SP, Munster PN, Britten CD, Gelmon K, Tolcher AW, Sharma A.

Cancer Chemother Pharmacol. 2008 Jun;62(1):97-109. Epub 2007 Sep 6.

PMID:
17805538
7.

A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.

Delaunoit T, Burch PA, Reid JM, Camoriano JK, Kobayash T, Braich TA, Kaur JS, Rubin J, Erlichman C.

Invest New Drugs. 2006 Jul;24(4):327-33.

PMID:
16502355
8.

Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.

Yamamoto N, Nokihara H, Yamada Y, Uenaka K, Sekiguchi R, Makiuchi T, Slapak CA, Benhadji KA, Tamura T.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1645-55. doi: 10.1007/s00280-013-2165-2. Epub 2013 Apr 25.

PMID:
23616084
9.

Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.

Veltkamp SA, Pluim D, van Tellingen O, Beijnen JH, Schellens JH.

Drug Metab Dispos. 2008 Aug;36(8):1606-15. doi: 10.1124/dmd.108.021048. Epub 2008 May 19.

10.

Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study.

Dueland S, Aamdal S, Lind MJ, Thomas H, Sandvold ML, Gaullier JM, Rasch W.

Acta Oncol. 2009;48(1):137-45. doi: 10.1080/02841860802183620.

PMID:
18607882
11.

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.

Bergman AM, Adema AD, Balzarini J, Bruheim S, Fichtner I, Noordhuis P, Fodstad O, Myhren F, Sandvold ML, Hendriks HR, Peters GJ.

Invest New Drugs. 2011 Jun;29(3):456-66. doi: 10.1007/s10637-009-9377-7. Epub 2010 Jan 12.

12.

Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer.

Dudek AZ, Larson T, Keshtgarpour M, Kumar P.

Am J Clin Oncol. 2007 Oct;30(5):481-6.

PMID:
17921707
13.

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, et al.

J Clin Oncol. 1991 Mar;9(3):491-8.

PMID:
1999720
14.

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.

Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J.

J Clin Oncol. 1998 Sep;16(9):2977-85.

PMID:
9738566
15.

Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.

Koolen SL, Witteveen PO, Jansen RS, Langenberg MH, Kronemeijer RH, Nol A, Garcia-Ribas I, Callies S, Benhadji KA, Slapak CA, Beijnen JH, Voest EE, Schellens JH.

Clin Cancer Res. 2011 Sep 15;17(18):6071-82. doi: 10.1158/1078-0432.CCR-11-0353. Epub 2011 Jul 13.

16.

Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.

Chabot GG, Armand JP, Terret C, de Forni M, Abigerges D, Winograd B, Igwemezie L, Schacter L, Kaul S, Ropers J, Bonnay M.

J Clin Oncol. 1996 Jul;14(7):2020-30.

PMID:
8683232
17.

Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.

Yuan Y, Cohen DJ, Love E, Yaw M, Levinson B, Nicol SJ, Hochster HS.

Cancer Chemother Pharmacol. 2011 Aug;68(2):371-8. doi: 10.1007/s00280-010-1493-8. Epub 2010 Oct 27.

PMID:
20978761
18.

Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.

Lim N, Lara PN Jr, Lau DH, Edelman MJ, Tanaka M, al-Jazayrly G, Houston J, Lauder I, Gandara DR.

Cancer Invest. 2003;21(1):7-13.

PMID:
12643004
19.

Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.

Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T.

J Clin Oncol. 1998 May;16(5):1795-802.

PMID:
9586893
20.

Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.

Peters GJ, Clavel M, Noordhuis P, Geyssen GJ, Laan AC, Guastalla J, Edzes HT, Vermorken JB.

J Chemother. 2007 Apr;19(2):212-21.

PMID:
17434832
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk